I have previously posted on FIRM (Focal Impulse and Rotor Modulation) ablations which appeared to show very promising results in industry sponsored trials.
However subsequently there was an independent trial (OASIS) which showed that FIRM ablations didn't even have the same success rate as standard RF PVI ablations. This paper was published in the JACC journal.
Now the JACC has retracted the paper which is an extreme and very unusual step. They quote issues with the OASIS trial, which appear to be relatively minor. A number of people smell a rat. There do appear to be numerous conflicts of interest.
Anyone with an interest in the way the pharma industry operates or medical science should read this article by John Mandrola: